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M. Vidal 5, A. Llombart-Cussac10, J. Cortés11, P. Galván3, B. Bermejo12, N. Martínez13, R. López14, S. Morales 15, I. Garau16,
L. Manso 17, J. Alarcón18, E. Martínez19, P. Villagrasa6, A. Prat 3,5,6,21✉ and P. Nuciforo 4,6,21✉
Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation
of immune cells within tumour microenvironment, as well as its dynamics during anti-HER2 treatment, is largely unknown. We here
investigate changes in tumour-immune contexture, as assessed by stromal tumour-infiltrating lymphocytes (sTILs) and by
multiplexed spatial cellular phenotyping, during treatment with lapatinib-trastuzumab in HER2+ BC patients (PAMELA trial).
Moreover, we evaluate the relationship of tumour-immune contexture with hormone receptor status, intrinsic subtype and
immune-related gene expression. sTIL levels increase after 2 weeks of HER2 blockade in HR-negative disease and HER2-enriched
subtype. This is linked to a concomitant increase in cell density of all four immune subpopulations (CD3+, CD4+, CD8+, Foxp3+).
Moreover, immune contexture analysis showed that immune cells spatially interacting with tumour cells have the strongest
association with response to anti-HER2 treatment. Subsequently, sTILs consistently decrease at the surgery in patients achieving
pathologic complete response, whereas most residual tumours at surgery remain inflamed, possibly reflecting a progressive loss of
function of T cells. Understanding the features of the resulting tumour immunosuppressive microenvironment has crucial
implications for the design of new strategies to de-escalate or escalate systemic therapy in early-stage HER2+ BC.
npj Precision Oncology            (2021) 5:23 ; https://doi.org/10.1038/s41698-021-00163-6
INTRODUCTION
The host immune system has an important role in HER2-positive
(HER2+) breast cancer (BC). Prior studies have revealed that ~55%
of HER2+ tumours have >10% of stromal tumour-infiltrating
lymphocytes (sTILs)1. From a clinical point of view, TILs are
associated with better survival outcomes in HER2+ early and
advanced BC1–3, higher pathological complete response (pCR)
rates after neoadjuvant anti-HER2-based chemotherapy2,4–7 and
higher response to trastuzumab plus pembrolizumab in the
advanced setting8. Thus, baseline TILs in HER2+ disease
determine prognosis and might contribute to the therapeutic
effects of anti-HER2-based treatments9,10.
Despite the recognised role of immune cells in HER2+ BC, the
composition, localisation and functional orientation of immune
cells within the tumour microenvironment (jointly referred to as
immune contexture), as well as the dynamics of TILs during and
after anti-HER2 treatment, are largely unknown. Limited and
inconsistent evidence is available regarding the prognostic impact
of TILs in residual tumours following neoadjuvant anti-HER2-based
chemotherapy. High TIL levels in residual disease have been
associated both with better outcome11, worse outcome12 and no
impact on prognosis13. A study by Ladoire S. and colleagues
evaluated the prognostic impact of different lymphocytic sub-
populations; it reported high CD8 and low Foxp3 cell infiltrates
after chemotherapy to be significantly associated with improved
long-term outcome14. This study thus further highlights the need
for a more comprehensive evaluation.
The current treatment standard of early-stage HER2+ BC is anti-
HER2-therapy plus chemotherapy. Thus, prior studies have not been
able to dissect whether the observed changes in the immune
microenvironment are owing to chemotherapy, anti-HER2 therapy,
or both. Studies without chemotherapy are the ideal scenario to
address the specific role of anti-HER2 therapy15,16. The neoadjuvant
PAMELA trial (SOLTI-1114)15 treated 151 patients with HER2+ BC
with trastuzumab and lapatinib (and endocrine therapy if the
tumour was hormone receptor [HR] positive) for 18 weeks. In this
study, sTILs at baseline and at day 15 differed significantly according
to PAM50 intrinsic subtype. Moreover, sTILs at baseline were found
significantly associated with pCR in the univariable analysis but not
in multivariable analysis. At day 15, a significant increase in sTILs
was observed in most patients; also, sTILs at day 15 were found
independently associated with pCR at multivariate analysis17.
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With this background, several questions can be addressed from
the PAMELA trial: (1) which cells compose immune infiltrate in early
HER2+ BC and how are they interacting with tumour cells?; (2) how
does this relate to the probability of achieving a pCR?; (3) which
subgroup of patients increases sTILs after 2 weeks of priming with
HER2-targeted treatment?; (4) how do these changes relate to the
probability of achieving a pCR?; (5) how do immune contexture
changes after anti-HER2 priming relate to the probability of
achieving a pCR?; (6) how are sTILs expressed at surgery following
neoadjuvant treatment? and (7) how is the presence of sTILs
associated with immune-related gene expression?
We here investigated changes in the tumour-immune microenvir-
onment following treatment with lapatinib and trastuzumab and the
relationship of sTILs with HR status, intrinsic subtype and immune-
related gene expression in patients with HER2+ BC from the
PAMELA trial. Moreover, we assessed immune contexture at baseline
and day 15 in patients with available samples by multiplexed spatial
cellular phenotyping (REMARK diagram, Supplementary Fig. 1). The
results from this analysis might help design new strategies to de-
escalate or escalate systemic therapy in HER2+ early BC.
RESULTS
A multiplexed imaging assay for immune microenvironment
characterisation
We developed a multiplexed immunohistochemistry (IHC) work-
flow (named next-generation IHC or next-generation impactor
(NGI)) comparable with that of conventional IHC. This workflow is
based upon iterative cycles of staining and destaining of the same
slide with different primary antibodies, individual slide digitalisa-
tion, virtual multiplexed digital image reconstruction and complex
image analyses (Fig. 1a). A six-plex panel was specifically designed
to interrogate the tumour-immune microenvironment and
included a tumour-related protein (cytokeratin), a functional
marker for proliferation (Ki67) and four immune-related T-cell
lineage markers (CD3, CD4, CD8 and Foxp3). The latter was
selected as established markers of T cells with an effector (CD3+
CD8+) and suppressor/regulatory (CD3+CD4+Foxp3+) functions.
The antibody staining of each target was initially optimised
using two different tissue controls (a normal tonsil and a BC) and
further validated on an independent series of HER2+ BC stained
by regular IHC to ensure consistent results among methods
(Supplementary Figs. 2 and 3). We evaluated marker specificity by
matching the staining obtained with each antibody to the known
histologic distribution and to staining with a conventional IHC
protocol: Ki67-stained cells in the germinal centre, and CD3-, CD4-
and CD8-stained cells predominantly in the mantle zone (Fig. 1b, c).
Furthermore, we evaluated the subcellular localisation of the
biomarkers and confirmed that staining of the transcription
factors Ki67 and Foxp3 were nuclear, whereas CD3, CD4 and CD8
were membrane.
The individual digitalised IHC images were aligned to obtain a
virtual multiplexed image (Fig. 1d), which was analysed using
Fig. 1 Multiplexed imaging assay. a Next-generation immunohistochemistry (NGI) workflow. An FFPE tissue section is stained, scanned and
destained six times. All the scanned images are aligned, image analysis is done to obtain the data and after doing all the quality check controls,
the data are analysed to obtain the final results. b Representative colour deconvoluted images of different biomarkers in the tonsil. From left to
right Foxp3+, CD3+, CD8+, CD4+ and Ki67+. Images at 6×. c Colour overlays of different biomarkers in the tonsil (CD3+ in red, CD8+, CD4+ and
Ki67+ in green from top to bottom). Images at 6×. d A representative example of all the stainings (Foxp3, CD4, KI67, CD8, CD3 and cytokeratin)
in breast cancer samples and virtual image reconstruction of some of them by assigning virtual colours to the deconvoluted images. Foxp3+ in
red, CD8+ in blue, CD3+ in green and cytokeratin in grey. The fine purple line in each image marks the tumour borders. Images at 5×.
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different image analysis algorithms developed for biomarker
densities, function and spatial analyses (Supplementary Fig. 4).
Immune microenvironment contexture
A total of 231 regions of interest (ROI) from 129 unique samples
had sufficient material for NGI analysis. All samples were stained
with a sequential IHC workflow that included a panel of six
antibodies for T cells subtyping (CD3, CD4, CD8 and Foxp3),
proliferation (Ki67) and tumour recognition (cytokeratin) plus
hematoxylin for counterstaining. Samples with total region of
interest (ROI) below 100,000 µm were excluded from the analysis.
After filter, a total of 114 samples (65 baseline and 49 day 15) from
75 patients were evaluable. An average (range) ROI of
7,764,692 µm2 (122,074–37,742,587) was profiled using an image
analysis pipeline for data extraction and analysis (see methods).
To identify the immune cell subpopulations within the samples, we
clustered the immune cells by canonical markers. We found that our
analytical pipeline was able to accurately classify immune cells even
when those with opposite identifiers were located in close proximity
to each other (Fig. 2a). Over a total of 1,217,249 cells identified, the
proportions of CD3+ immune subsets across all patients’ samples
were 47% CD8+CD4−Foxp3−, 30% CD4+Foxp3−CD8−, 11%
CD4+Foxp3+CD8− and 13% CD8−CD4−Foxp3− (Fig. 2b).
To chart the immune landscape in HER2+ BC, we then
quantified the number of immune cell populations per area
across patients. We found large variability in immune cells
content, which was confirmed by pathological sTILs scoring on
H&E staining (Supplementary Table 1, Fig. 2c–f, Supplementary
Figs. 5–6). Densities of all immune cell subtypes were all positively
correlated with the number of sTILs (Spearman Rho, CD3+= 0.63,
CD8+= 0.65, CD4+= 0.54, Foxp3+= 0.615, P < .0001, Supplemen-
tary Fig. 7) assessed by a board-certified pathologist according to
international TILs working group recommendation18. Densities of
all immune cell subtypes negatively correlated with the percen-
tage of tumour area in the sample (CD3+=−0.209, P= 0.028;
CD8+=−0.205, P= 0.031; CD4+=−0.184, P= 0.053, Foxp3+=
−0.203, P= 0.033, Supplementary Fig. 8a).
To evaluate the spatial organisation of the tumour-immune
landscape in HER2+ BC, we developed a method for assessing
spatial proximity enrichment of each immune cell subtype from
the tumour. We quantified the number of positive cells for each
marker located within three regions of different distance from the
tumour: A, intratumoural; B, proximal stroma within 30 µm and C,
distal stroma >30 µm from the tumour, respectively (Fig. 2g).
Higher immune cells densities were found in the proximal
peritumoural regions (B) compared with intratumoural (A) and
distal peritumoural (C) locations although the difference was
statistically significant only between location B and C for all
immune subtypes (P values for comparison between immune cell
density in area B and C, CD3= 0.017, CD8= 0.014, CD4= 0.045,
Foxp3= 0.023, Fig. 2h, Supplementary Fig. 9).
To determine the level of activation of immune cells within the
tumour microenvironment, we developed a method to quantify
the proportion of proliferating immune cells within the stromal
compartment by virtually multiplexing individual immune cell
markers with Ki67 staining obtained from the same slide (Fig. 2i).
The proportion of proliferating immune cells over total proliferat-
ing cells (Ki67+ tumour and immune cells) was 35%, with tumour
cells representing the main proliferative cell subtype within the
tissue, as expected (Supplementary Fig. 10). The proportion of
proliferating stromal immune cells was positively correlated with
the amount of tumour area in the sample (Spearman Rho,
CD3+Ki67+= 0.397, CD8+Ki67+= 0.331, CD4+Ki67+= 0.414,
Foxp3+Ki67+= 0.395, P < 0.001, Supplementary Fig. 11).
Spatial analysis revealed a differential distribution according to
immune cells proximity to the tumour, with a decreasing
proportion of proliferating CD3+ (P < 0.001), CD8+ (P < 0.001),
CD4+ (P < 0.001) and Foxp3+ (P < 0.001) T cells from the
intratumoural region (A) to the distal location (C) (Fig. 2j,
Supplementary Fig. 12, Supplementary Table 2).
Immune contexture analysis according to HR status
To evaluate if the tumour-immune microenvironment differed
according to HR status, we compared the composition, spatial
distribution and functional activity of immune subtypes in HR+
and HR− HER2+ BC.
In the whole sample area, densities of all immune cell subtypes
were significantly higher in HR− as compared with HR+ tumours
[HR− median (interquartile range) CD3+ 1669(1818), CD8+ 689
(955), CD4+ 629(884), Foxp3+ 187(215); HR+ median (interquartile
range) CD3+ 828(863), CD8+ 383(520), CD4+ 361(472), Foxp3+ 57
(89); P values, CD3+= 0.009, CD8+= 0.009, CD4+= 0.019 and
Foxp3+ < 0.001, Supplementary Fig. 13a]. As expected, these
findings paralleled what observed for sTILs both at baseline and
day 15, for which however the difference between HR− and HR+
tumours was only significant after 2 weeks of anti-HER2 treatment
(median sTILs at day 15 20% vs 10% in HR− and HR+ tumours,
respectively, P < 0.001).
The number of immune cells was higher in HR− compared with
HR+ across all peritumoural stroma locations, whereas their
intratumoural content did not differ significantly according to HR
status (Supplementary Fig. 14, Supplementary Table 3).
We further investigated if immune cells activation was
influenced by tumour HR status. The proportion of proliferating
immune cells was higher in HR- as compared with HR+ tumours
(Wilcoxon, CD3+ P= 0.007; CD8+ P= 0.011; CD4+ P= 0.009)
except for Foxp3+ (P= 0.710) (Supplementary Fig. 13b, Supple-
mentary Table 4). These differences were maintained across all
peritumoural stroma locations (Supplementary Fig. 15). In HR+, a
higher mean proportion of Foxp3+ proliferating cells (13.2%) was
observed compared with proliferating CD3+ (5.6%), CD4+ (6.2%)
and CD8+ (5.4%) (Kruskal–Wallis test, P < 0.001). The ratio of
proliferating Foxp3+/CD8+ was significantly higher in HR+ as
compared to HR− tumours (2.29 vs 1.33, P= 0.004).
Immune contexture analysis according to PAM50 molecular
subtype
We have previously shown that, within HER2+ early BC, HER2-
enriched PAM50 tumours present significantly higher sTILs as
compared with other PAM50 subtypes, both at baseline (10% vs
5%; P= 0.006) and at day 15 (20% vs 10%; P < 0.001)17. Tumour-
immune contexture analysis showed no significant difference in
immune cell subsets densities according to PAM50 subtype at
baseline (Table 1). The fraction of proliferating (Ki67+) cells for all
four immune cell subpopulations (CD3+, CD4+, CD8+, Foxp3+)
was numerically higher in basal-like tumours, whereas luminal
tumours showed the lowest fraction of proliferating cells (Table 1,
Fig. 3a, Supplementary Fig. 16a). However, this difference was not
statistically significant.
After 2 weeks of HER2-targeted treatment, tumours classified as
HER2-enriched or Basal-like by PAM50 at baseline showed
significantly higher density of all 4 immune subsets as compared
to Luminal A and B tumours (Table 1, Fig. 3b, Supplementary Fig.
16b). Similar to baseline, the fraction of proliferating (Ki67+) cells
for all four immune cell subpopulations (CD3+, CD4+, CD8+,
Foxp3+) at day 15 was numerically higher in basal-like tumours,
while luminal tumours showed the lowest fraction of proliferating
cells, although the difference was not statistically significant (Table 1,
Fig. 3c, Supplementary Fig. 16c).
Immune contexture dynamics under anti-HER2 treatment
As previously described17, overall sTILs levels at day 15 were
significantly higher than those in paired baseline samples. When
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Fig. 2 Multiplexed spatial cellular phenotyping of breast cancer. a Representative example of the analytical pipeline classifying immune
cells (top left) and colour deconvoluted images with red, green and blue colours assigned to Foxp3+, CD4+ and CD8+, respectively (bottom)
and magenta for CD3+ (top right). Images at 25×. b Proportions of CD3+ immune subsets across all patients’ samples (up), baseline samples
(down to the left) and day 15 samples (down to the right). CD8+, Foxp3+, CD4+ and CD3+-only in blue, orange, gray and yellow. c
Representative examples of breast cancers with low (up), medium (middle) and high (down) T-cell densities. Images at 5×. d CD3+ density
results across the entire population of HER2+ breast cancers. Samples are ordered from lowest to highest. e Proportions of CD8+ (blue),
Foxp3+ (orange), CD4+ (gray) and CD3+ only (yellow) cells for all patients’ samples. f Stromal tumour-infiltrating lymphocytes (TILs) in breast
cancer samples with available NGI data. g Representative example of the spatial analysis areas defined by the image analysis algorithm using
cytokeratin as tumour mask. Intratumoural (a, in red), proximal peritumoural stroma within 30 µm (b, in yellow) and distal peritumoural stroma
>30 µm from the tumour (c, in gray) regions are shown. Images at 5×. h Boxplots of immune cells densities (CD8+ and Foxp3+) according to
spatial location. Boxplot legend: centre line: median; bounds of box: interquartile range (IQR); whiskers: highest and lowest value excluding
outliers (Q3+ 1.5*IQR to Q1− 1.5*IQR); markers beyond the whiskers: potential outliers. i Representative example of CD4+, Foxp3+, CD8+ and
KI67+ sequential immunohistochemistry and co-expression analyses for T cells activity assessment on the same tissue slide (top panel). The
colour green, red, blue and green is assigned, respectively, to each individual staining for visualisation purpose, co-expression analyses and
virtually multiplexed images (first image composed by CD4, Foxp3 and CD8 and second image composed by Foxp3, CD8 and Ki67; co-
expression in yellow). Images at 50×. j Boxplots of the proportion of proliferating immune cells (CD8+ and Foxp3+) according to spatial
location. Boxplot legend: centre line: median; bounds of box: interquartile range (IQR); whiskers: highest and lowest value excluding outliers
(Q3+ 1.5*IQR to Q1− 1.5*IQR); markers beyond the whiskers: potential outliers.
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we looked at differences according to subtype, a statistically
significant increase in sTILs was observed in HR-negative (P <
0.001) and HER2-enriched subtype (P= 0.001), but not in HR-
positive and non-HER2-enriched PAM50 subtypes (Fig. 4a, Table
2). Within the HER2-enriched subtype, an increase in sTILs levels
was more evident in HR-negative disease (Table 2).
To identify which immune component was responsible for the
increase in sTILs levels after priming with 2 weeks of anti-HER2
treatment, we analysed changes in the density of each immune
cell subpopulation between these two timepoints by multiplexed
spatial cellular phenotyping. We found large differences in both
activity and densities of the immune cells when comparing
untreated tumours with on-treatment samples. In fact, densities of
all immune cells subtypes increased at day 15 [median
(interquartile range) CD3+ 1462(1453), CD8+ 688(526), CD4+ 534
(684), Foxp3+ 166(219)] as compared to baseline [median
(interquartile range) CD3+ 832(1795), CD8+ 364(841), CD4+ 445
(684), Foxp3+ 83(141)] tumours (P values, significant only for
CD8+= 0.04, Supplementary Table 1, Supplementary Fig. 13c).
When individual patient immune cell density data from the 39
patients with paired baseline-day 15 samples were considered, a
significant increase in both CD8+ and Foxp3+ cell density was
observed at day 15 (Supplementary Fig. 6).
In on-treatment samples (day 15), 50% of all immune cells were
CD8+ as compared with 42% of baselines samples (Fig. 2b). CD3+
and CD8+ immune cell densities were inversely correlated with
tumour area in on-treatment (day 15) samples (Spearman’s rho,
CD3+ −0.367 P= 0.020, CD8+ −0.368; P= 0.010) but not in
baseline samples (CD3+ −0.060; P= 0.620, CD8+ −0.014; P=
0.915; Supplementary Fig. 8b–c).
Spatial analysis revealed that the increase in the number of
immune cells at day 15 was significant in the intratumoural and
proximal peritumoural regions but not in the distal stromal region
(Supplementary Fig. 17). Upon treatment, the number of proliferat-
ing immune cells per area uniformly decreased across all location
compared to baseline pretreatment samples (P < 0.001 for all
comparisons, Supplementary Figs. 13d and 18, Supplementary Table
5). Lower percentages of proliferating immune cells at day 15 were
not significantly associated with lower tumour cellularity evaluated
on the same sample (Spearman Rho, CD3+Ki67+= 0.089,
CD8+Ki67+= 0.053, CD4+Ki67+= 0.185, Foxp3+Ki67+= 0.246, P >
0.05 for all comparisons) (Supplementary Fig. 11b, c).
Paired multiplex IHC (mIHC) data from both baseline and day
15 samples were available from 39 patients and were used to assess
changes in densities of immune cell subpopulations in day 15 and
baseline paired samples according to baseline PAM50 intrinsic
subtype and HR status (Supplementary Table 6). Although the
decrease in percentages of proliferating immune cells (all four
immune subpopulations) at day 15 was consistently observed across
all subgroups, a statistically significant increase in immune cells
density (all four immune subpopulations) at day 15 was only
observed in HR-negative and HER2-enriched subtype (all P values <
0.05 except for CD4+in HER2-enriched tumours P= 0.055), but not
in HR-positive and non-HER2-enriched PAM50 subtypes. Similar to
prior observations of sTILs levels, the increase was numerically more
evident in HR-negative disease than in HER2-enriched tumours.
Tumour-immune contexture analysis and the probability of
achieving a pCR
As previously described17, higher sTILs were significantly asso-
ciated with pCR and lower residual cancer burden scores, both at
baseline and after 2 weeks of anti-HER2 treatment.
In HR-positive disease or non-HER2-enriched subtype, no
consistent change in sTILs at day 15 versus baseline was found
Table 1. Immune cell density at baseline and after 2 weeks of anti-HER2 treatment according to baseline PAM50 intrinsic subtype.
Immune cell density at baseline
Immune cell Subpopulation Immune cell density by intrinsic subtype: median (IQR)
Luminal A (N= 11) Luminal B (N= 6) HER2-enriched (N= 43) Basal-like (N= 5) p value
CD3+ 781 (200–1035) 1277 (696–1372) 1073 (367–2313) 644 (225–1921) 0.419
CD8+ 217 (77–383) 461 (350–481) 475 (125–1018) 166 (64–648) 0.562
CD4+ 352 (84–445) 525 (340–773) 507 (151–1096) 403 (144–502) 0.374
Foxp3+ 43 (13–93) 28 (28–83) 88 (45–202) 52 (49–176) 0.178
%Ki67+CD3+ 6 (4–7) 5 (3–8) 9 (4–14) 8 (5–17) 0.178
%Ki67+CD4+ 6 (4–10) 7 (1–8) 9 (4–13) 9 (6–17) 0.184
%Ki67+CD8+ 5 (2–9) 3 (3–7) 8 (4–12) 9 (5–19) 0.188
%Ki67+Foxp3+ 18 (14–20) 15 (0–15) 15 (9–18) 19 (15–27) 0.064
Immune cell density at day 15
Immune cell
subpopulation
Immune cell density by intrinsic subtype: median (IQR)
Luminal A (N= 7) Luminal B (N= 6) HER2-enriched (N= 33) Basal-like (N= 3) p value
CD3+ 435 (193–747) 749 (710–896) 1669 (899–2461) 1544 (501–1544) 0.008
CD8+ 296 (66–367) 442 (405–492) 769 (481–1417) 583 (275–583) 0.007
CD4+ 204 (102–322) 272 (228–295) 713 (361–1136) 629 (158–629) 0.011
Foxp3+ 44 (13–48) 37 (22–39) 214 (93–300) 195 (46–195) 0.004
%Ki67+CD3+ 3 (2–3 1 (1–1) 4 (2–7) 7 (3–7) 0.051
%Ki67+CD4+ 3 (3–3) 1 (1–2) 5 (2–7) 10 (5–10) 0.062
%Ki67+CD8+ 2 (1–2) 1 (1–1) 3 (2–8) 6 (2–6) 0.058
%Ki67+Foxp3+ 7 (5–13) 2 (1–9) 7 (3–12) 15 (5–15) 0.412
Normal-like N= 0; significant p values in bold.
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according to the type of pathological response (Supplementary
Table 7). Both in HER2-enriched subtype and HR-negative disease,
a consistent increase in sTILs at day 15 versus baseline was found
regardless of the type of pathological response (Fig. 4a and
Supplementary Table 7).
To identify if the prognostic impact of sTILs might be different
according to immune contexture, we then analysed the impact of
immune cells composition, activity and spatial interaction with
tumour cells on pCR. Both at baseline and at day 15, no significant
difference in immune cell subpopulation densities was observed
between tumours achieving or not achieving pCR, despite
numerically higher densities of all four immune subpopulations
were observed in tumours achieving pCR at day 15 (Fig. 5a).
After that, to determine whether T-cell activation status
associated with the probability of pCR, we compared the rates
of proliferating (Ki67+) immune cells in tumours achieving or not
achieving pCR. No statistically significant association was
observed, although Odds ratios (OR) for % of proliferating cells
and pCR were consistently higher at baseline as compared with
day 15 for all immune cell subpopulations except Foxp3+ (Fig. 5b).
Finally, we analysed immune cells subpopulation densities
separately according to their spatial distribution. Although only
some of the associations reached statistical significance, the
association between higher immune cell density and pCR was
consistently stronger for more proximal compartments (intratu-
moural and proximal peritumoural stroma) as compared with the
Fig. 3 Immune cell density according to intrinsic subtype. a Boxplots of the proportion of proliferating immune cells (CD8+ and Foxp3+) at
baseline according to baseline intrinsic subtyping. b Boxplots of immune cells densities (CD8+ and Foxp3+) at day 15 according to baseline
intrinsic subtyping. c Boxplots of the proportion of proliferating immune cells (CD8+ and Foxp3+) at day 15 according to baseline intrinsic
subtyping. Boxplot legend: centre line: median; bounds of box: interquartile range (IQR); whiskers: highest and lowest value excluding outliers
(Q3+ 1.5*IQR to Q1 – 1.5*IQR); markers beyond the whiskers: potential outliers.
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Fig. 4 Changes in sTILs across timepoints and correlation with gene expression. a Changes in TILs between baseline and day 15 according
to hormone receptor [HR] status, subtype (HER2-enriched [HER2-E]) and response (pathological complete response [pCR] vs residual disease
[RD]). Lines are coloured according to TIL dynamics: increase (red), stable (blue) or decrease (green). b Changes in TIL levels between day 15
and surgery according to response: pathological complete response [pCR] vs residual disease [RD]. Lines are coloured according to TIL
dynamics: increase (red), stable (blue), or decrease (green). c Changes in TIL levels between baseline, day 15 and surgery in the overall study
cohort and according to response (pathological complete response [pCR] vs residual disease [RD]), hormone receptor [HR] status and
PAM50 subtype. Lines are coloured according to TIL dynamics: increase between baseline and day 15 followed by an increase between day 15
and surgery (red); increase between baseline and day 15 followed by stable or decrease between day 15 and surgery (orange); stable or
decrease between baseline and day 15 followed by an increase between day 15 and surgery (blue); stable or decrease between baseline and
day 15 followed by stable or decrease between day 15 and surgery (green). d Venn diagram representing overlaps in genes upregulated in
relation to increase in TIL levels across the three timepoints.
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distal stroma compartment for all four immune cell subpopula-
tions. Moreover, the association between higher immune cell
density and pCR was stronger at day 15 as compared with
baseline (Fig. 5c).
Changes in sTILs between day 15 and surgery
At surgery, median sTILs levels were 10% (quartile 1–3: 5–20).
Paired sTILs data from day 15 and surgery samples were available
for 124 patients (82.1%). An increase and a decrease of sTILs
between day 15 and surgery were observed in 26.4% (24/91) and
33.0% (30/91) of tumours, respectively, whereas for 40.7% (37/91)
of tumours the same percentage of sTILs was reported at day 15
and at surgery. Compared with day 15, a significant decrease in
sTILs was observed at surgery in tumours achieving a pCR (mean
difference −21.5%, 95% CI −33.3 to −9.7, P= 0.002, Fig. 4b), but
not in patients with residual disease at time of surgery (mean
difference −0.9%, 95% CI −4.1–+2.4, P= 0.548, Fig. 4b). 89.7% of
residual tumours (non-pCR) had sTILs above ≥5%. The distribution
of residual tumours (non-pCR) according to sTILs at surgery was
10.3% (sTILs < 5%), 38.1% (sTILs 5–9%), 22.7% (sTILs 10–19%),
16.5% (sTILs 20–39%) and 12.4% (sTILs ≥ 40%). Distribution of
tumour samples (non-pCR and pCR) according to sTIL levels at the
three timepoints is presented in Supplementary Tables 8–9 and
Supplementary Fig. 19. A decrease in sTILs in tumours achieving
pCR was observed irrespectively of HR status and intrinsic subtype
(Supplementary Table 10). In tumours not achieving a pCR, no
significant tendency was observed. Finally, TILs at surgery were
not found statistically significantly different according to the type
of pathological response (median sTIL levels at surgery 10% (5–20)
vs 5% (1–10) in patients with residual disease and achieving pCR,
respectively; P= 0.662).
sTILs dynamics across timepoints
Different tumour-infiltrating lymphocytes dynamics observed
across the three timepoints (N= 122 patients with sTILs data
from all three timepoints) are recapitulated in Supplementary
Table 11 and Fig. 4c. The most frequently observed pattern (N=
32, 26%) was an increase in TILs from baseline to day 15 followed
by a decrease from day 15 to surgery. This pattern was observed
especially in HR-negative tumours, HER2-enriched tumours and
tumours achieving pCR (Fig. 4c). Changes in sTILs levels between
surgery and baseline paired samples according to the achieve-
ment of pCR, HR status and PAM50 subtypes are reported in
Supplementary Table 12.
sTILs vs gene expression
To evaluate genes associated with sTILs, we explored data from
413 samples with paired gene expression and sTIL data (from all
three timepoints mixed: baseline N= 148; day 15 N= 133; surgery
N= 132). A total of 555 BC-related genes were evaluated,
including 72 immune-related genes (Supplementary Table 13).
Using a quantitative significance of microarrays (SAM) analysis, 36
upregulated genes were found associated with sTIL levels (false
discovery rate (FDR) < 1%) (Supplementary Table 14), the top
upregulated gene being MS4A1 (CD20). Functional annotation of
the 36 genes using DAVID annotation tool19 revealed that 50% of
them were significantly involved in immune response (e.g., CD3G,
CD8A, CD4 and LAG3) and regulation of the immune system
process (e.g., IDO1, IL6R, STAT1 and PD1), 33% of them were
involved in lymphocyte activation (e.g., CD84, CD86, CD3G and
CD4) and 28% of them involved in T-cell activation (e.g., CD8A, PD-
L1, RELB and CD4).
When a similar analysis was performed within each timepoint
separately, similar results were obtained (Fig. 4d; Supplementary
Tables 15–17). Among the different genes significantly associated
with sTIL levels, 10 (MS4A1, PD1, CD8A, CD19, IKBKE, IDO1, TAP1,
TYMP, CD3G and LAG3) were found consistently associated with
sTILs across all timepoints. This 10-gene list was found highly
enriched (FDR < 1%) for immune genes tracking activated CD8
T cells (e.g., CD8A, CD3G, LAG3, PD1). The correlation coefficients
of the expression of these genes with baseline sTILs ranged from
0.52 in gene CD8A to 0.34 in gene TYMP.
DISCUSSION
To our knowledge, our report is the first one to provide new
insights into TIL variations and immune contexture during HER2-
targeted therapy in the absence of chemotherapy. Moreover,
using a novel mIHC technique, immune infiltrate at baseline and
after 2 weeks of anti-HER2 treatment was characterised in its
immune cell subpopulations and analysed according to proximity
to tumour cells and activity (using co-expression of Ki67 marker to
identify proliferating immune cells).
First, in early HER2+ treatment-naive BC, tumour-immune
contexture analysis showed no significant difference in immune
cell subsets densities according to intrinsic subtyping. However, we
observed a significantly higher proportion of proliferating immune
cells in HR− as compared with HR+ tumours, except for Foxp3+
and consistently observed a numerically higher percentage of
proliferating immune cells in basal-like tumours and HER2-enriched
tumours and a numerically lower percentage of proliferating
Table 2. Changes in TILs between day 15 and baseline according to PAM50 intrinsic subtype and hormone receptor (HR) status.
N (pairs) mean difference 95% confidence interval p value
HR-positive 70 +2.1% −0.7–+4.8 0.199
HR-negative 61 +12.5% +5.5–+19.6 <0.001
HER2-enriched 85 +8.8% 3.5–14.0 0.001
HER2-enriched and HR− 53 +12.1% 4.3–20.0 0.004
HER2-enriched and HR+ 32 +3.2% −2.0–+8.4 0.235
Non-HER2-enriched 46 +3.5% −0.3–+7.4 0.120
Non-HER2-enriched and HR− 8 +15.0% −3.7–+33.7 0.106
Non-HER2-enriched and HR+ 38 +1.1% −1.6–+3.9 0.584
Basal-like 7 +11.6% −8.6–+31.7 0.201
Normal-like 2 +9.5% −365.3–+384.3 1.000
Luminal B 15 +3.9% −1.7–+ 9.6 0.236
Luminal A 22 +0.18% −2.16–+2.5 0.959
Significant p values in bold.
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immune cells in luminal tumours. However, it should be pointed
out that the very limited number of non-HER2-enriched tumours
identified in the PAMELA trial, in line with what expected in early
HER2+ BC, significantly limits the power of these analyses.
Second, after 2 weeks of dual HER2-targeted therapy, a general
increase in sTILs is observed. However, this increase appears to be
selectively present in HR-negative and HER2-enriched subtype,
regardless of pathological response at surgery, but not in HR-
positive and non-HER2-enriched subtypes. Immune contexture
analysis highlighted that this increase is not linked to a selective
increase of one immune cell subpopulation, but a concomitant
increase in cell density of all four immune subpopulations (CD3+,
Fig. 5 Immune cell density and pathological complete response. a Odds ratios (95% confidence interval) for pathologic complete response
(pCR) for 10% increases in TIL levels and 1000 cells/mm2 increases in immune cell density evaluated on baseline and Day 15 (on-treatment)
samples. b Odds ratios (95% confidence interval) for pathologic complete response (pCR) for increases in % of proliferating immune cells for
each immune cell subpopulation evaluated on baseline and day 15 (on-treatment) samples. c Odds ratios (95% confidence interval) for
pathologic complete response (pCR) for 1000 cells/mm2 increases in immune cell density according to immune cell localisation evaluated on
baseline and day 15 (on-treatment) samples.
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CD4+, CD8+, Foxp3+) after anti-HER2 treatment. However, a
significant shift was observed for CD8+ cytotoxic T cells
subpopulation, which represented 50% of all tumour-associated
immune cells in on-treatment samples.
As previously observed for sTIL levels, increase in specific
immune cell subpopulation densities was observed in HER2-
enriched subtype and HR-negative tumours, but not in non-HER2-
enriched PAM50 subtypes and HR-positive tumours.
Consistently with these trends, immune infiltrate was radically
modified after 2 weeks of anti-HER2 treatment. In fact, after
priming with anti-HER2 treatment, tumours that were HER2-
enriched at baseline showed higher densities of all four immune
cell subpopulations, highlighting the differential activation of the
immune system towards the disease after priming with anti-HER2
treatment according to tumour biology.
Moreover, the association between pCR and immune infiltrate
was stronger at day 15 than at baseline, both for sTILs and specific
immune subpopulations, especially when immune cells intratu-
mour/more proximal to the tumour were considered, pointing out
the potential biological role of immune activation after anti-HER2
priming in early HER2+ BC.
Subsequently, a general decrease in sTIL levels is observed at
surgery. However, this decrease is driven by tumours achieving
pCR, whereas no significant trend was seen in patients with
residual disease at the time of surgery. Tumours achieving pCR are
characterised by an increase in sTIL levels after 2 weeks of anti-
HER2 treatment and a decrease in sTIL levels at surgery. This might
be linked to downregulation of immune response after clearing
tumour cells. However, although the increased infiltration of
immune cells observed after HER2 priming is inversely correlated
with tumour cellularity at day 15, hinting that these immune cells
might have been actively clearing tumour cells during the first
2 weeks of HER2-targeted treatment, their activity (in terms of
fraction of proliferating immune cells) was significantly and
homogeneously reduced after 2 weeks of HER2-targeted treat-
ment, independently for the amount of residual tumour in the
sample and tumour characteristics, thus pointing out that immune
exhaustion processes might already be at work at this early
timepoint. This observation might by relevant to address the
question of which might be the ideal timing of potential
combination with immunotherapy in early HER2+ BC.
The association between pCR and decrease in sTIL levels at
surgery has also been shown after chemotherapy-containing
neoadjuvant treatment for HER2+ BC12. However, the same study
observed that higher sTIL levels at surgery, in presence of residual
disease, were associated with an adverse disease-free survival,
suggesting that post-neoadjuvant sTILs might be unable to exert
their antitumour function, possibly owing to an immunosuppres-
sive microenvironment or T-cell exhaustion. A limitation of the
present study is that immune infiltrate subtyping by mIHC was not
available for surgical samples with residual disease and therefore
functional assessment of this infiltrate could not be evaluated.
Moreover, the true prognostic value of sTIL levels after dual HER2
blockade without chemotherapy remains unknown and long-term
follow-up data from the PAMELA trial is not currently available to
provide more information on this point.
However, the presence of high sTIL levels in most residual
tumours at surgery might imply that these patients might be good
candidates for clinical trials evaluating adjuvant immune check-
point inhibitors. The KATE2 trial, which tested the addition of the
anti-PD-L1 antibody atezolizumab to trastuzumab emtansine in
metastatic BC HER2+ BC patients previously treated with
trastuzumab and taxanes, despite missing its primary endpoint,
identified a numerically longer PFS and higher 1-year OS in
patients with PD-L1+ and TIL high (≥5%) tumours20. These
hypothesis-generating data might support the evaluation of PD1/
PD-L1 inhibitors to trastuzumab emtansine in the post-
neoadjuvant setting to further improve the prognosis of patients
with inflamed residual disease.
Tumour heterogeneity has a predominant role in modulating
immune activation in HER2+ BC. Indeed, not only HR-negative and
HER2-enriched tumours had higher sTIL levels at baseline, but the
impact of tumour biology was observed even more clearly after
exposure to HER2-targeted treatment. Non-luminal subtypes
showed the highest increases in sTIL levels between baseline and
day 15, whereas luminal subtypes showed modest/no increase. Even
within HER2-enriched tumours, an increase in sTILs was predomi-
nantly seen in HR-negative tumours rather than in the HR-positive
subgroup. Indeed, HR positivity appeared to be associated with the
capacity/incapacity of HER2+ BC to inflame during dual HER2
blockade (without chemotherapy), more than to baseline sTIL levels.
These observations were also supported by immune contexture
analyses showing a significantly lower proportion of CD8+Ki67+
T cells and higher ratio of proliferating Foxp3+/CD8+ in HR+ as
compared with HR- tumours. Whether this is due to specific
regulation of the immune system by hormone signalling (or
endocrine treatment, as all HR-positive BCs also received hormo-
notherapy in the PAMELA trial), or if reduced activation of immunity
in these tumours is linked to reduced cell death after HER2-targeted
treatment and reduced antigen exposure, remains unclear and
might hopefully be the subject for further investigation.
In conclusion, in early HER2+ BC, an increase in sTIL levels is
observed following 2 weeks of dual HER2 blockade, in HR-negative
disease and HER2-enriched subtype. Immune contexture analysis
revealed that the strongest impact on pCR was achieved when
immune cells spatially interacted with tumour cells. Afterward,
sTILs consistently decreased at surgery in patients achieving a
pCR, whereas most residual tumours at surgery remained
inflamed, possibly reflecting a progressive loss of function of
T cells, which is already evident after 2 weeks of treatment.
Understanding the features of the resulting tumour immunosup-
pressive microenvironment has crucial implications for the success
of checkpoint blockade and adoptive T-cell transfer therapies.
Beyond modulating baseline immune activation, tumour biology
also has a role in modulating the dynamic activation of the
immune system after exposure to HER2-targeted treatment. This
should be taken into account as the role of immunity and
immunotherapy is further assessed in HER2+ BC.
METHODS
PAMELA clinical trial
The main results of the neoadjuvant PAMELA phase II trial (NCT01973660)
have been previously reported15. In this study, 151 early HER2+ BC
patients were treated with the combination of lapatinib (1000mg daily)
and trastuzumab (8mg/kg i.v. loading dose followed by 6mg/kg) for
18 weeks. Patients with HR-positive disease also received letrozole or
tamoxifen according to menopausal status (Supplementary Fig. 1a). In the
PAMELA trial, tissue collection was mandatory as it was used for primary
endpoint determination. Tumour samples were collected at three time-
points according to the protocol: baseline (within 28 days preceding
treatment start), day 15 (a ± 5 days window was admitted, but collection of
samples the closest as possible to preplanned timepoint was warmly
suggested) and surgery (Supplementary Fig. 1a and sample flow by
REMARK diagram in Supplementary Fig. 1b). A minimum of 2 core
formalin-fixed paraffin-embedded (FFPE) samples were collected by tru-cut
biopsy at each timepoint (except at surgery). In case of multifocality,
samples were collected from the same lesion. Samples were primarily used
for pre-specified protocol analyses, which included central HER2, ER and PR
confirmation by regular IHC, Ki67 by IHC and molecular subtyping by
PAM50 gene expression assays. The mIHC analyses performed in the
present study were post-hoc and used left-over samples.
The PAMELA trial was conducted under Good Clinical Practice guidelines
and the Declaration of Helsinki. The study protocol was approved by
independent ethics committees at each centre (trial centres listed at
clinicaltrials.gov, NCT01973660). All patients provided written informed
consent.
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sTILs evaluation
Stromal TILs at baseline, day 15 and surgery were centrally evaluated on
whole sections of tumour tissue stained with H&E blinded from clinical-
pathological and outcome data. Percentages (%) of TILs at baseline and
day 15 were scored in slides of core biopsies. sTILs were quantified
according to the 2014 Guidelines developed by the International TILs
Working Group18,21. The reproducibility of this method has been described
previously2.
Multiplex IHC (NGI)
Baseline (N= 65) and day 15 (N= 49) biopsies from 75 patients were
analysed using a custom mIHC 6-plex panel, based on iterative cycles of
staining and destaining of the same slide with different primary antibodies,
individual slide digitalisation, virtual multiplexed digital image reconstruc-
tion and complex image analyses.
Before cutting, FFPE blocks were cooled to −10 °C and 3 μm sections
were cut with a microtome. Sections were collected on positively charged
Superfrost glass slides and dried overnight at 37 °C. The first IHC staining
was performed (information of all the protocols on Supplementary Table
18) in Discovery Ultra Autostainer (Ventana Medical Systems, Tucson AZ).
Mono AEC/Plus (#K050; PALEX) was used as the chromogen.
The slides were mounted with aqueous-based mounting medium. The
stained slides were digitalised at 20× using the NanoZoomer 2.0HT
(Hamamatsu Photonics, Japan). After digitalisation, coverslips were taken
and slides were put in increasing alcohol solutions until 100% and then in
decreasing alcohols until water before slides were loaded in the Discovery
Ultra autostainer for the next immunostaining.
Any residual primary antibody was stripped by an ‘extra' antigen
retrieval step before the staining process is repeated for the following
primary antibody. Heat-induced antigen retrieval was done using ULTRA
Cell Conditioning 2 (ULTRA CC2, Ventana Medical Systems, Tucson AZ) for
8 minutes at 100 °C and DISCOVERY Cell Conditioning 1 (DISCOVERY CC1,
Ventana Medical Systems, Tucson AZ) for 40minutes at 95 °C to block the
previous antibody and the process was repeated consecutively six times.
To avoid primary antibody cross-reactivity between cycles owing to
incomplete stripping, we used several strategies. First, we added an extra
antigen retrieval step before the next cycle of staining to prevent any
remnant reactivity to primary or secondary antibodies used in the first
cycle. Second, the protocol alternated rabbit and mouse primary
antibodies to reduce cross-reactivity. Third, the sequence of primary
antibodies alternated nuclear (Ki67 and Foxp3), membrane (CD3, CD8,
CD4) and cytoplasmic (CK) markers (Supplementary Fig. 20).
The sequential staining procedure was automatised, thus significantly
reducing the hands-on time (1-hour per staining cycle) and duration of the
entire process (3 days per 6-plex panel run in 30 slides).
The image analysis pipeline was the following one: first, images were
uploaded into VISIOPHARM® (VIS) Image Analysis Software (Visiopharm
Integrator System version 2019.02.1.6005, Visiopharm, Denmark) for
registration. Images were automatically aligned and fused into a single
virtual digital image (VDI) using the Tissuealign® module of VIS (order of
alignment: Foxp3, CD3, CD8, CD4, Ki67, cytokeratin). After alignment,
images were analysed with custom-developed algorithms created using
the Author® module of VIS (algorithms in Supplementary Material).
After this, we performed automatic tissue recognition of the aligned
slides and the selected areas were reviewed by a pathologist, who
manually defined the ROI, which included the tumour and surrounding
peritumoural stroma (the tumour bed in case of complete regression) and
excluded normal and/or necrotic area. Following this, we ran T-cell density
APP was run on the entire slides to obtain global results. The T-cell
application (detailed in Supplementary Table 19) uses a cell classification
method based on form and size and a pixel-colour intensity threshold
method to classify the cells into Foxp3, CD3, CD4, CD8 cells on one hand,
and uses the Ki67 staining to inform about the percentage of the cell
populations that are proliferating on the other hand. Any brown stained
nucleus was considered a positive cell.
We then applied a third APP (location APP), which uses the PANCK
staining to divide the ROI created by the pathologist into three different
ROIs: the tumour area (A), the stroma within 30 µm from tumour (B) and
the stroma >30 µm from tumour (C). For that purpose, we used HDAB-DAB
feature, which enhances the brown staining corresponding to the PANCK
staining (A). Dilation was used to create B and C ROIs. After applying the
location APP to the data set, we used the T-cell APP to obtain densities and
proliferation rates of different cell populations across different locations.
Created APPs were trained by a biotechnologist expert in image analysis
and the results validated by a board-certified pathologist. Data were finally
reported as densities of each category of cells in the tumoural area in
general, for each location, and the proliferation rate of each of the cell
categories.
Gene expression analysis
Samples from all three timepoints were analysed using the same
methodology. First, a section of FFPE breast tissue was examined with
H&E staining to confirm the diagnosis and determine the tumour surface
area. RNA purification was performed after macrodissection, when needed,
to avoid normal breast contamination. RNA was extracted from FFPE
material using the High Pure FFPET RNA isolation kit (Roche, Indianapolis,
IN, USA) following the manufacturer’s protocol. RNA samples were
quantified at the NanoDrop spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, USA).
A minimum of ~100 ng of total RNA was used to measure the expression
of 555 BC-related genes and five housekeeping genes (ACTB, MRPL19,
PSMC4, RPLP0 and SF3A1) using the nCounter platform (Nanostring
Technologies; Seattle, Washington, USA22). Data were log base
2–transformed and normalised using the housekeeping genes. The
complete list of genes, which included immune-related genes (e.g.,
CD8A, CD4, PD1 and PD-L1), can be found in Supplementary Table 13.
Intrinsic molecular subtyping at baseline was determined using the
previously reported PAM50 subtype predictor23.
Statistical analysis
Spearman test was used for correlation analysis and Mann–Whitney U test
and Wilcoxon test were used for all the density, location and proliferation
analyses. To determine differences in the distribution of TIL levels or
immune cell density across subgroups Mann–Whitney U and
Kruskal–Wallis test were used according to number of subgroups.
Significant changes in sTILs or immune cell density between two
timepoints were determined using paired Wilcoxon tests. The association
of each variable with pCR was determined by univariate logistic regression
analysis. As per study protocol, pCR was defined as the absence of residual
invasive cancer in the breast following neoadjuvant therapy (ypT0/is). OR
with a 95% confidence interval were estimated. All statistical tests were
two-sided and considered significant when p < 0.05.
When recapitulating TIL dynamics across the three timepoints, any
increase/decrease in sTIL levels were taken into account and sTILs were
only defined as unchanged if the same % of TILs were present at two
subsequent timepoints.
To identify genes whose expression was significantly different according
to sTIL levels as a continuous variable, we used a quantitative SAM analysis
with an FDR < 1%. Pearson correlations were used to evaluate the
association of expression of a single gene with sTILs expression. Biologic
analysis of gene lists was performed with DAVID annotation tool (http://
david.abcc.ncifcrf.gov/)19.
All statistical analyses were performed using the R software 3.6.1.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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